{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T23:38:11Z","timestamp":1775173091015,"version":"3.50.1"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/ http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Background and objectives:<\/jats:title>\n            <jats:p>Non-alcoholic fatty liver disease (NAFLD) is characterized by ectopic deposition of fat in the liver, in the absence of other secondary causes of fat buildup. The relationship between NAFLD, including alanine aminotransferase (ALT), and glycated haemoglobin (HbA1c), is important for predicting the severity of disease and prognosis. This study aims to investigate the association of HbA1c in type 2 diabetes mellitus (T2DM) patients with NAFLD via measuring the ALT levels.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and methods:<\/jats:title>\n            <jats:p>This retrospective cross-sectional study enroled 130 patients with T2DM and NAFLD. The association between levels of HbA1c and ALT in patients of NAFLD with controlled and uncontrolled T2DM, respectively, was investigated. Stratification was done based on gender and diabetic control, using HbA1c levels as a marker of glycemic control. Serum ALT levels were also compared in both groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The mean age of the participants was 50.2\u00b15.7 years. The total participants were 130, of which 77 (59.3%) were females and 53 (40.7%) were males. The numbers of patients having uncontrolled T2DM (HbA1c&gt;7%), and controlled T2DM (HbA1c &lt;7%) were 78 (60%) and 52 (40%), respectively. Moreover, 46 (35.3%) females and 32 (24.7%) males had uncontrolled T2DM, and 31 (23.8%) females and 21 (16.2%) males had controlled T2DM. The mean ALT level for uncontrolled and controlled T2DM in female patients was found to be 24.6\u00b13.4 and 13.5\u00b12.4, respectively, (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt;0.05). For male patients, it was found to be 54.0\u00b14.9 and 29.1\u00b15.4, respectively (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.008).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>There is a positive association between elevated HbA1c and ALT levels in T2DM patients with NAFLD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ms9.0000000000001875","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T10:00:31Z","timestamp":1709028031000},"page":"1929-1932","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["The interplay between diabetes and non-alcoholic fatty liver disease: a cross-sectional study from Pakistan"],"prefix":"10.1097","volume":"86","author":[{"given":"Ayesha","family":"Akhtar","sequence":"first","affiliation":[{"name":"Internal Medicine, Khyber Teaching Hospital, Peshawar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huda","family":"Ijaz","sequence":"additional","affiliation":[{"name":"Internal Medicine, Allama Iqbal Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Waseem","sequence":"additional","affiliation":[{"name":"Dow University of Health Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Ijaz","family":"Khan","sequence":"additional","affiliation":[{"name":"Medicine Unit, Naas General Hospital, Kildare"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasir","family":"Saif","sequence":"additional","affiliation":[{"name":"Internal Medicine, University Hospital Kerry, Kerry, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haris","family":"Iqbal","sequence":"additional","affiliation":[{"name":"King Edward Medical University, Lahore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syeda Aasia","family":"Batool","sequence":"additional","affiliation":[{"name":"Nishtar Medical university, Multan, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Usha","family":"Kumari","sequence":"additional","affiliation":[{"name":"Medicine, Dow University of Health Sciences, Karachi"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salim","family":"Surani","sequence":"additional","affiliation":[{"name":"Texas A&M University, College Station, TX"},{"name":"Research Collaborator, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aarash","family":"Khan","sequence":"additional","affiliation":[{"name":"Herat University, Herat, Afghanistan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,4]]},"reference":[{"key":"R2-20250806","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/jdi.13756","article-title":"Non-alcoholic fatty liver disease and type\u20092 diabetes: an update","volume":"13","author":"Lee","year":"2022","journal-title":"J Diabetes Investig"},{"key":"R3-20250806","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jhep.2013.04.027","article-title":"A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver","volume":"59","author":"Pais","year":"2013","journal-title":"J Hepatol"},{"key":"R4-20250806","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jhep.2014.11.034","article-title":"Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management","volume":"62","author":"McPherson","year":"2015","journal-title":"J Hepatol"},{"key":"R5-20250806","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.12669\/pjms.38.7.6289","article-title":"Clinicopathologicalfeatures and related risk factors of Type-2 diabetes mellitus complicated with nonalcoholic fatty liver","volume":"38","author":"Chen","year":"2022","journal-title":"Pak J Med Sci"},{"key":"R6-20250806","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"R7-20250806","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2337\/dc20-1997","article-title":"Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening","volume":"44","author":"Lomonaco","year":"2021","journal-title":"Diabetes Care"},{"key":"R8-20250806","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1210\/jc.2015-1966","article-title":"High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels","volume":"100","author":"Portillo-Sanchez","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"R9-20250806","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0065-2423(08)60362-5","article-title":"The clinical significance of alterations in transaminase activities of serum and other body fluids","volume":"1","author":"Wroblewski","year":"1958","journal-title":"Adv Clin Chem"},{"key":"R10-20250806","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1503\/cmaj.1040752","article-title":"Liver enzyme alteration: a guide for clinicians","volume":"172","author":"Giannini","year":"2005","journal-title":"CMAJ"},{"key":"R11-20250806","first-page":"256","article-title":"The relationship between glycaemic control and non-alcoholic fatty liver disease in nigerian type 2 diabetic patients","volume":"110","author":"Afolabi","year":"2018","journal-title":"J Natl Med Assoc"},{"key":"R12-20250806","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S2213-8587(22)00003-1","article-title":"A global view of the interplay between non-alcoholic fatty liver disease and diabetes","volume":"10","author":"Stefan","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R13-20250806","doi-asserted-by":"crossref","first-page":"639548","DOI":"10.3389\/fendo.2021.639548","article-title":"Non-alcoholic fatty liver disease in obese youth with insulin resistance and type 2 diabetes","volume":"12","author":"Scapaticci","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R14-20250806","doi-asserted-by":"crossref","first-page":"BSR20193996","DOI":"10.1042\/BSR20193996","article-title":"HbA1c may contribute to the development of non-alcoholic fatty liver disease even at normal-range levels","volume":"40","author":"Chen","year":"2020","journal-title":"Biosci Rep"},{"key":"R15-20250806","doi-asserted-by":"crossref","first-page":"902393","DOI":"10.3389\/fpubh.2022.902393","article-title":"Association between serum aminotransferases and risk of new-onset cardiometabolic disease in a healthy chinese population: a cohort study","volume":"10","author":"Lan","year":"2022","journal-title":"Front Public Health"},{"key":"R16-20250806","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.3390\/ijms21113863","article-title":"The role of insulin resistance and diabetes in nonalcoholic fatty liver disease","volume":"21","author":"Fujii","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R17-20250806","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1007\/s11695-019-03880-x","article-title":"The HAALT non-invasive scoring system for NAFLD in obesity","volume":"29","author":"Sheth","year":"2019","journal-title":"Obes Surg"},{"key":"R18-20250806","doi-asserted-by":"crossref","first-page":"107885","DOI":"10.1016\/j.jdiacomp.2021.107885","article-title":"Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis","volume":"35","author":"Sagara","year":"2021","journal-title":"J Diabetes Complications"},{"key":"R19-20250806","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.pcd.2016.12.001","article-title":"Clinical correlates of persistently elevated liver enzymes in type 2 diabetic outpatients","volume":"11","author":"Giandalia","year":"2017","journal-title":"Prim Care Diabetes"},{"key":"R20-20250806","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"R21-20250806","doi-asserted-by":"crossref","first-page":"e13335","DOI":"10.1111\/ijcp.13335","article-title":"Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"73","author":"Aso","year":"2019","journal-title":"Int J Clin Pract"},{"key":"R22-20250806","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1111\/jdi.13279","article-title":"Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, open-label, three-arm, active control study","volume":"11","author":"Kinoshita","year":"2020","journal-title":"J Diabetes Investig"},{"key":"R23-20250806","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.bbrc.2017.12.143","article-title":"Metformin ameliorates activation of hepatic stellate cells and hepatic fibrosis by succinate and GPR91 inhibition","volume":"495","author":"Nguyen","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"R24-20250806","first-page":"899","article-title":"Combination therapy with pioglitazone\/exenatide\/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT)","volume":"24","author":"Lavynenko","year":"2022","journal-title":"Diabetes ObesMetab"},{"key":"R25-20250806","doi-asserted-by":"crossref","first-page":"106165","DOI":"10.1016\/j.ijsu.2021.106165","article-title":"STROCSS 2021: Strengthening the Reporting of cohort, cross-sectional and case-control studies in Surgery","volume":"96","author":"Mathew","year":"2021","journal-title":"Int J Surg"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000001875","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T13:05:23Z","timestamp":1754485523000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000001875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,28]]},"references-count":24,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000001875","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,28]]},"assertion":[{"value":"2023-08-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}